Johnson & Johnson (J&J) has announced a new group within its pharma-focused Janssen division that will tackle global public health.
The new group, known as Janssen GPH, will oversee R&D and access strategy development for Janssen’s growing portfolio of transformational medicines in markets with great unmet public health need.
“With this new group, we’ve adopted a more focused approach to further develop and introduce our most promising medicines, and look forward to advancing a sustainable platform that will make a significant impact on the lives of people around the world,” said Janssen chairman Paul Stoffels.
Janssen GPH will be jointly led by Adrian Thomas, VP of global market access, global commercial strategy operations, and global public health, and Wim Parys, VP, R&D global public health.
It will be responsible for clinical and product development and creating and implementing innovative new access strategies for a growing portfolio of pharmaceuticals, diagnostics, and services for diseases affecting emerging markets and areas with limited resources.
“We have the ability to leverage our R&D skills and expertise in collaborations that support innovative solutions for the developing world. We hope to create more targeted medicines for treating and preventing disease,” said Parys.
As part of this strategy Janssen GPH will develop and help implement innovative pricing and results-based financing models for resource-limited regions, while at the same time creating sustainable, long-term solutions based on country ownership and accountability for health services and outcomes.
These new strategies will be integrated with those developed by Janssen’s Global Access and Partnerships Program (GAPP), which ensures affordable and sustainable access to the company’s portfolio of HIV medicines in resource-limited countries.
Janssen GPH aims to be the main point of contact for continued collaboration with global public health stakeholders, and invites innovative, international, and multi-sectorial collaborations to tackle key challenges in global public health.
“We are applying our expertise where we can make the biggest impact,” said Thomas. “Our goal is to address seemingly intractable health challenges in new and unexpected ways.”